BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27431310)

  • 1. G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.
    Agarwal P; Jackson SP
    Cancer Lett; 2016 Oct; 380(2):467-475. PubMed ID: 27431310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
    Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
    Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G9a coordinates with the RPA complex to promote DNA damage repair and cell survival.
    Yang Q; Zhu Q; Lu X; Du Y; Cao L; Shen C; Hou T; Li M; Li Z; Liu C; Wu D; Xu X; Wang L; Wang H; Zhao Y; Yang Y; Zhu WG
    Proc Natl Acad Sci U S A; 2017 Jul; 114(30):E6054-E6063. PubMed ID: 28698370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
    Wu YH; Hong CW; Wang YC; Huang WJ; Yeh YL; Wang BJ; Wang YJ; Chiu HW
    Cancer Lett; 2017 Aug; 400():79-88. PubMed ID: 28450160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
    Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
    Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells.
    Cao YP; Sun JY; Li MQ; Dong Y; Zhang YH; Yan J; Huang RM; Yan X
    Acta Pharmacol Sin; 2019 Aug; 40(8):1076-1084. PubMed ID: 30765842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
    Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
    Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
    Ren A; Qiu Y; Cui H; Fu G
    Biochem Biophys Res Commun; 2015 Mar; 459(1):10-7. PubMed ID: 25634693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights for the design of protein lysine methyltransferase G9a inhibitors.
    Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
    Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
    Tao H; Li H; Su Y; Feng D; Wang X; Zhang C; Ma H; Hu Q
    Mol Cell Biochem; 2014 Sep; 394(1-2):23-30. PubMed ID: 24833465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
    Zhang K; Wang J; Yang L; Yuan YC; Tong TR; Wu J; Yun X; Bonner M; Pangeni R; Liu Z; Yuchi T; Kim JY; Raz DJ
    Mol Cancer; 2018 Oct; 17(1):153. PubMed ID: 30348169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
    Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
    J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
    Colyn L; Bárcena-Varela M; Álvarez-Sola G; Latasa MU; Uriarte I; Santamaría E; Herranz JM; Santos-Laso A; Arechederra M; Ruiz de Gauna M; Aspichueta P; Canale M; Casadei-Gardini A; Francesconi M; Carotti S; Morini S; Nelson LJ; Iraburu MJ; Chen C; Sangro B; Marin JJG; Martinez-Chantar ML; Banales JM; Arnes-Benito R; Huch M; Patino JM; Dar AA; Nosrati M; Oyarzábal J; Prósper F; Urman J; Cubero FJ; Trautwein C; Berasain C; Fernandez-Barrena MG; Avila MA
    Hepatology; 2021 Jun; 73(6):2380-2396. PubMed ID: 33222246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G9a - An Appealing Antineoplastic Target.
    Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
    Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.
    Zhang J; He P; Xi Y; Geng M; Chen Y; Ding J
    Oncotarget; 2015 Feb; 6(5):2917-27. PubMed ID: 25595900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
    Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between the H3K36me3 and H4K16ac histone epigenetic marks in DNA double-strand break repair.
    Li L; Wang Y
    J Biol Chem; 2017 Jul; 292(28):11951-11959. PubMed ID: 28546430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G9a inhibition induced PKM2 regulates autophagic responses.
    Ahmad F; Dixit D; Joshi SD; Sen E
    Int J Biochem Cell Biol; 2016 Sep; 78():87-95. PubMed ID: 27417236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
    Jiang Y; Yam JC; Chu WK
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.